EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
نویسندگان
چکیده
منابع مشابه
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib improves survival of lung cancer as second- or third-line therapy. However, after an initial response, most patients will recur, particularly within the central nervous system. The present study reports the case of a 27-yr-old nonsmoking male presenting with a metastatic lung adenocarcinoma with EGFR exon 19 del...
متن کاملPeritoneal relapse from lung adenocarcinoma after a response to EGFR-TKI.
kinase inhibitors (EGFR-TKIs) for EGFR-mutated elderly non-small cell lung cancer (NSCLC) patients has been reported (1,2). It is supposed that EGFR-TKIs are increasingly prescribed for them. In NSCLC patients, metastases to meningeal as well as peritoneal space are rare (3,4). However, carcinomatous meningitis, which attracts attention as a recurrence site of the patients who received EGFR-TKI...
متن کاملThe Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
OBJECTIVES Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial. METHODS Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed. RESULTS The overall s...
متن کاملNew EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.
Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recurrent lung adenocarcinoma treated with icotinib. The patient obtained a partial remission in 4 weeks that was maintained 14 months. Retrospective examination of EGFR mutations confirmed he had a sensitive mutation (exon 19 deletion). This case supports that ico...
متن کاملThe role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
Epidermal growth factor receptor (EGFR) T790M mutation has shown to be associated with the clinical outcomes of patients after initial EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy in EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, its predictive role in EGFR-TKI re-challenge remains unknown. The present study was aimed to explore the correlation between T790M mutation and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2008
ISSN: 0903-1936,1399-3003
DOI: 10.1183/09031936.00162307